| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 15 | 2025 | 834 | 4.310 |
Why?
|
| Cardiovascular Diseases | 17 | 2023 | 1877 | 3.980 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 107 | 3.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2021 | 716 | 3.050 |
Why?
|
| Heart Failure | 12 | 2024 | 2131 | 2.790 |
Why?
|
| Eicosapentaenoic Acid | 6 | 2020 | 79 | 2.690 |
Why?
|
| Stroke | 7 | 2023 | 957 | 2.230 |
Why?
|
| Cholesterol, LDL | 6 | 2022 | 558 | 1.980 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 626 | 1.970 |
Why?
|
| Troponin I | 3 | 2024 | 96 | 1.610 |
Why?
|
| Anticholesteremic Agents | 4 | 2022 | 231 | 1.590 |
Why?
|
| Dyslipidemias | 3 | 2019 | 229 | 1.550 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 69 | 1.520 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2024 | 233 | 1.420 |
Why?
|
| Coronary Disease | 3 | 2023 | 637 | 1.310 |
Why?
|
| Hypercholesterolemia | 4 | 2020 | 226 | 1.280 |
Why?
|
| Inferior Wall Myocardial Infarction | 2 | 2018 | 8 | 1.220 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 86 | 1.220 |
Why?
|
| Lipids | 4 | 2019 | 513 | 1.210 |
Why?
|
| Hypolipidemic Agents | 2 | 2020 | 176 | 1.190 |
Why?
|
| Coronary Angiography | 5 | 2024 | 421 | 1.170 |
Why?
|
| Electrocardiography | 4 | 2024 | 958 | 1.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 1009 | 1.030 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 1003 | 1.030 |
Why?
|
| Risk Factors | 20 | 2025 | 10036 | 0.970 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 17 | 0.900 |
Why?
|
| Brain Ischemia | 2 | 2023 | 258 | 0.900 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 39 | 0.880 |
Why?
|
| Myocardium | 3 | 2018 | 986 | 0.870 |
Why?
|
| Humans | 63 | 2025 | 123254 | 0.860 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 233 | 0.830 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 52 | 0.820 |
Why?
|
| Aged | 25 | 2023 | 19173 | 0.810 |
Why?
|
| Ultrasonography, Interventional | 1 | 2024 | 196 | 0.780 |
Why?
|
| Dietary Supplements | 3 | 2021 | 475 | 0.770 |
Why?
|
| Biomarkers | 9 | 2024 | 2951 | 0.750 |
Why?
|
| Galectin 3 | 1 | 2021 | 31 | 0.740 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2023 | 274 | 0.730 |
Why?
|
| Cardiology | 3 | 2021 | 474 | 0.730 |
Why?
|
| Lipid Regulating Agents | 1 | 2020 | 6 | 0.720 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 3 | 0.710 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 1078 | 0.710 |
Why?
|
| Vascular Stiffness | 1 | 2021 | 75 | 0.700 |
Why?
|
| Denervation | 1 | 2020 | 29 | 0.700 |
Why?
|
| Veterans | 3 | 2021 | 1735 | 0.680 |
Why?
|
| Risk Assessment | 7 | 2025 | 3336 | 0.660 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 84 | 0.650 |
Why?
|
| Troponin T | 4 | 2024 | 245 | 0.640 |
Why?
|
| Eligibility Determination | 1 | 2019 | 37 | 0.630 |
Why?
|
| Biological Products | 1 | 2020 | 113 | 0.630 |
Why?
|
| Drug Costs | 1 | 2019 | 60 | 0.620 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 35 | 0.620 |
Why?
|
| Middle Aged | 23 | 2025 | 26073 | 0.620 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2018 | 11 | 0.620 |
Why?
|
| Smoking Cessation | 1 | 2020 | 197 | 0.610 |
Why?
|
| Docosahexaenoic Acids | 1 | 2019 | 66 | 0.610 |
Why?
|
| Medication Adherence | 2 | 2019 | 387 | 0.600 |
Why?
|
| Incretins | 1 | 2018 | 25 | 0.580 |
Why?
|
| Anticoagulants | 3 | 2020 | 580 | 0.580 |
Why?
|
| Secondary Prevention | 1 | 2019 | 212 | 0.580 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 135 | 0.570 |
Why?
|
| Stents | 1 | 2024 | 878 | 0.570 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 363 | 0.570 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 65 | 0.570 |
Why?
|
| Pyrimidines | 1 | 2020 | 373 | 0.560 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 850 | 0.560 |
Why?
|
| Cardiovascular System | 1 | 2018 | 101 | 0.560 |
Why?
|
| United States | 16 | 2022 | 10663 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3549 | 0.540 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 750 | 0.530 |
Why?
|
| Pandemics | 2 | 2021 | 1100 | 0.520 |
Why?
|
| Kidney | 2 | 2020 | 1343 | 0.520 |
Why?
|
| Treatment Outcome | 11 | 2024 | 12165 | 0.500 |
Why?
|
| Peptide Fragments | 3 | 2023 | 747 | 0.490 |
Why?
|
| Hypertension | 2 | 2021 | 1284 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 373 | 0.480 |
Why?
|
| Male | 29 | 2025 | 60310 | 0.480 |
Why?
|
| Ezetimibe | 3 | 2019 | 95 | 0.470 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 429 | 0.450 |
Why?
|
| Hospitalization | 2 | 2019 | 1739 | 0.450 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 6385 | 0.430 |
Why?
|
| Female | 26 | 2025 | 65598 | 0.430 |
Why?
|
| Blood Pressure | 3 | 2024 | 1326 | 0.410 |
Why?
|
| Sitosterols | 2 | 2009 | 9 | 0.390 |
Why?
|
| Berberine | 2 | 2009 | 10 | 0.390 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2021 | 657 | 0.380 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 96 | 0.380 |
Why?
|
| Glucosides | 3 | 2020 | 46 | 0.370 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1637 | 0.360 |
Why?
|
| Tobacco, Smokeless | 2 | 2020 | 13 | 0.360 |
Why?
|
| Benzhydryl Compounds | 3 | 2020 | 67 | 0.360 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1084 | 0.350 |
Why?
|
| Dicarboxylic Acids | 3 | 2019 | 34 | 0.350 |
Why?
|
| Prognosis | 6 | 2025 | 4515 | 0.350 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2852 | 0.330 |
Why?
|
| Europe | 2 | 2020 | 350 | 0.320 |
Why?
|
| Congresses as Topic | 2 | 2020 | 169 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1237 | 0.310 |
Why?
|
| Cholesterol | 2 | 2009 | 528 | 0.310 |
Why?
|
| Triglycerides | 3 | 2022 | 562 | 0.310 |
Why?
|
| Fatty Acids | 3 | 2019 | 338 | 0.300 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 70 | 0.300 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 265 | 0.300 |
Why?
|
| Phytosterols | 1 | 2008 | 28 | 0.300 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 2115 | 0.290 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 665 | 0.290 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 489 | 0.270 |
Why?
|
| Heart Rate | 2 | 2018 | 587 | 0.250 |
Why?
|
| Mutation | 1 | 2018 | 5765 | 0.230 |
Why?
|
| Angiopoietin-like Proteins | 2 | 2022 | 12 | 0.230 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3382 | 0.230 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 143 | 0.220 |
Why?
|
| Interleukin-18 | 1 | 2023 | 60 | 0.220 |
Why?
|
| Postmenopause | 2 | 2020 | 125 | 0.220 |
Why?
|
| Fishes | 1 | 2023 | 41 | 0.210 |
Why?
|
| Age of Onset | 1 | 2025 | 581 | 0.210 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 539 | 0.210 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 1142 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2023 | 6030 | 0.200 |
Why?
|
| Radial Artery | 1 | 2022 | 26 | 0.200 |
Why?
|
| Animals | 7 | 2023 | 33837 | 0.200 |
Why?
|
| Proprotein Convertase 9 | 1 | 2022 | 67 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2023 | 395 | 0.190 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 47 | 0.190 |
Why?
|
| Adult | 12 | 2025 | 29079 | 0.190 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 406 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 151 | 0.180 |
Why?
|
| Tobacco Use | 1 | 2020 | 24 | 0.180 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 1413 | 0.180 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.180 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 38 | 0.180 |
Why?
|
| Telecommunications | 1 | 2020 | 19 | 0.180 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 33 | 0.180 |
Why?
|
| Vitamin K | 1 | 2020 | 35 | 0.180 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2021 | 52 | 0.180 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 33 | 0.180 |
Why?
|
| Oligonucleotides | 1 | 2020 | 88 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 95 | 0.170 |
Why?
|
| Echocardiography | 2 | 2023 | 1049 | 0.170 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 74 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2019 | 373 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2021 | 156 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2020 | 61 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 58 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 29 | 0.170 |
Why?
|
| Protective Factors | 1 | 2020 | 84 | 0.170 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 35 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 114 | 0.170 |
Why?
|
| Angina Pectoris | 1 | 2019 | 57 | 0.170 |
Why?
|
| Phenotype | 2 | 2020 | 4227 | 0.170 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 57 | 0.160 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 81 | 0.160 |
Why?
|
| Heart Ventricles | 2 | 2021 | 763 | 0.160 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 25 | 0.160 |
Why?
|
| Radiation Dosage | 1 | 2019 | 134 | 0.160 |
Why?
|
| Radiation Exposure | 1 | 2019 | 43 | 0.160 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.160 |
Why?
|
| RNAi Therapeutics | 1 | 2019 | 17 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 77 | 0.160 |
Why?
|
| RNA Interference | 1 | 2020 | 496 | 0.160 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2018 | 17 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 196 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 332 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 197 | 0.150 |
Why?
|
| Monocytes | 1 | 2020 | 345 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 262 | 0.150 |
Why?
|
| Paraplegia | 1 | 2018 | 91 | 0.150 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 114 | 0.150 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 100 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 153 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 349 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 218 | 0.140 |
Why?
|
| Cysts | 1 | 2018 | 100 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 496 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 360 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1688 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 165 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 8867 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 177 | 0.140 |
Why?
|
| Cause of Death | 1 | 2019 | 463 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 203 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2020 | 678 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 150 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 1245 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2019 | 862 | 0.130 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 108 | 0.130 |
Why?
|
| Adolescent | 5 | 2021 | 19131 | 0.130 |
Why?
|
| Incidence | 2 | 2025 | 3052 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 623 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2020 | 482 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 434 | 0.130 |
Why?
|
| Thrombosis | 1 | 2020 | 518 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 458 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2020 | 520 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2019 | 527 | 0.120 |
Why?
|
| Testosterone | 1 | 2020 | 530 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 683 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 606 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 248 | 0.120 |
Why?
|
| Time Factors | 3 | 2021 | 6222 | 0.120 |
Why?
|
| Aging | 1 | 2022 | 1185 | 0.120 |
Why?
|
| Action Potentials | 1 | 2018 | 501 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 192 | 0.120 |
Why?
|
| Lipoproteins | 2 | 2022 | 177 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2018 | 884 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2020 | 669 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1523 | 0.100 |
Why?
|
| Genotype | 1 | 2018 | 2537 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5049 | 0.090 |
Why?
|
| Population Groups | 1 | 2010 | 29 | 0.090 |
Why?
|
| Prevalence | 3 | 2022 | 2407 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2018 | 4705 | 0.080 |
Why?
|
| Child | 2 | 2020 | 24263 | 0.080 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 16 | 0.080 |
Why?
|
| Comorbidity | 2 | 2021 | 1498 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2018 | 4499 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 940 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1218 | 0.060 |
Why?
|
| Genome, Human | 1 | 2010 | 1265 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 13918 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 36 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2586 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 37 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2020 | 16056 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3664 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 3680 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 50 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 110 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 183 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 168 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 15 | 0.040 |
Why?
|
| Lisinopril | 1 | 2019 | 25 | 0.040 |
Why?
|
| Amlodipine | 1 | 2019 | 22 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2019 | 54 | 0.040 |
Why?
|
| Metoprolol | 1 | 2019 | 22 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 169 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 78 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 68 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 446 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 723 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 243 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2018 | 619 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2017 | 122 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 257 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 293 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2017 | 162 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 678 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1265 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 697 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 396 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 378 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 807 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 264 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 997 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1611 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1741 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2806 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2844 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3045 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1075 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3239 | 0.020 |
Why?
|
| Human Genome Project | 1 | 2010 | 55 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 52 | 0.020 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2009 | 13 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2009 | 88 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 239 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 410 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 419 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 186 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2009 | 306 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 1565 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1745 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 17546 | 0.010 |
Why?
|